Lantern Pharma Inc (LTRN)

Mar 04, 2026

Institution Moves: What are Lantern Pharma Incs recent SEC filings showing2025 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn

Mar 04, 2026

Feb 28, 2026

What are Lantern Pharma Inc.’s recent SEC filings showingJuly 2025 Review & High Accuracy Trade Alerts - mfd.ru

Feb 28, 2026

Feb 28, 2026

LTRN Should I Buy - Intellectia AI

Feb 28, 2026

Feb 25, 2026

LTRN Technical Analysis & ETF Price Forecast - Intellectia AI

Feb 25, 2026

Feb 25, 2026

Bull Run: What is Lantern Pharma Incs P E ratio telling usWeekly Market Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn

Feb 25, 2026

Feb 23, 2026

LTRN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 23, 2026

Feb 14, 2026

LTRN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Feb 14, 2026

Feb 12, 2026

Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition - Bitget

Feb 12, 2026

Feb 10, 2026

Aug Gainers: Can Lantern Pharma Inc. stock sustain institutional interestMarket Trend Report & Weekly High Potential Stock Alerts - mfd.ru

Feb 10, 2026

Feb 10, 2026

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026 - Business Wire

Feb 10, 2026

Feb 10, 2026

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Asheville Citizen Times

Feb 10, 2026

Jan 31, 2026

Growth Report: How much upside does GWRE haveMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn

Jan 31, 2026

Jan 26, 2026

Patterns Watch: Is Lantern Pharma Inc stock undervalued right nowJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn

Jan 26, 2026

Jan 26, 2026

RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 - Corpus Christi Caller-Times

Jan 26, 2026

Jan 22, 2026

Lantern Pharma to Set Up AI Center of Excellence in Bengaluru to Scale RADR Platform - Digital Health News

Jan 22, 2026

Jan 21, 2026

FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas - Investing.com Nigeria

Jan 21, 2026

Jan 20, 2026

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas - PharmiWeb.com

Jan 20, 2026

Jan 20, 2026

Lantern Pharma (LTRN) Secures Orphan Drug Designation for LP-284 - GuruFocus

Jan 20, 2026

Jan 17, 2026

Lantern Pharma Establishes New AI Centre Of Excellence, Agentic Labs Hub In Bengaluru - Voice Of HealthCare

Jan 17, 2026

Jan 16, 2026

Lantern Pharma Expands Global AI Footprint with Bengaluru Center of Excellence - eHealth Magazine

Jan 16, 2026

Jan 16, 2026

Critical Comparison: Lantern Pharma (NASDAQ:LTRN) versus Praxis Precision Medicines (NASDAQ:PRAX) - Defense World

Jan 16, 2026

Jan 15, 2026

FDA Grants Orphan Drug Status to Lantern Pharma's Treatment for Sarcoma (LTRN) - GuruFocus

Jan 15, 2026

Jan 15, 2026

Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally - Indian Pharma Post

Jan 15, 2026

Jan 14, 2026

Recap Report: Whats the outlook for Lantern Pharma Incs sectorQuarterly Risk Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn

Jan 14, 2026

Jan 13, 2026

Lantern Pharma establishes AI Centre of Excellence and Advanced Agentic Labs in Bengaluru - BioSpectrum India

Jan 13, 2026

Jan 12, 2026

History Review: Is Lantern Pharma Inc stock a hidden gemGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn

Jan 12, 2026

Jan 12, 2026

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RAD - PharmiWeb.com

Jan 12, 2026

Jan 12, 2026

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies - 01net

Jan 12, 2026

Jan 12, 2026

Lantern Pharma IncEstablishes Ai Center Of Excellence In Bengaluru - TradingView — Track All Markets

Jan 12, 2026

Jan 08, 2026

Is Lantern Pharma Inc. stock a contrarian buyJuly 2025 Highlights & AI Forecasted Stock Moves - Улправда

Jan 08, 2026

Jan 07, 2026

Why Lantern Pharma Inc. stock attracts global investorsEarnings Date Calendar & Top Analyst Picks Available for Free - Улправда

Jan 07, 2026

Jan 07, 2026

Lantern Pharma (NASDAQ:LTRN) Stock Price Up 6.2% – What’s Next? - Defense World

Jan 07, 2026

Jan 01, 2026

What analysts say about Lantern Pharma Inc stockMarket Capitalization Trends & Superior Capital Growth - earlytimes.in

Jan 01, 2026

Dec 31, 2025

Lantern Pharma Inc Stock Analysis and ForecastMACD Histogram Signals & Fast Profit Trading Strategies - earlytimes.in

Dec 31, 2025

Dec 22, 2025

Is Lantern Pharma Inc a good long term investmentResistance Breakout Alerts & Learn to Trade with Real-Time Feedback - earlytimes.in

Dec 22, 2025

Dec 21, 2025

Sentiment Recap: Is Lantern Pharma Inc. stock a safe buy before earningsWeekly Profit Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn

Dec 21, 2025

Dec 20, 2025

What Wall Street predicts for Lantern Pharma Inc. stock priceJuly 2025 Update & Verified Entry Point Signals - Улправда

Dec 20, 2025

Dec 20, 2025

Lantern Pharma’s AI Bet Needs 2026 Trial Wins - Finimize

Dec 20, 2025

Dec 19, 2025

What momentum indicators show for Lantern Pharma Inc. stockEarnings Miss & AI Optimized Trade Strategies - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Why Lantern Pharma Inc. stock remains resilientNew Guidance & Target Return Focused Stock Picks - Улправда

Dec 18, 2025

Dec 16, 2025

Lantern Pharma (NASDAQ:LTRN) Shares Down 6.4% – Should You Sell? - Defense World

Dec 16, 2025

Dec 15, 2025

Lantern Pharma Earnings Notes - Trefis

Dec 15, 2025

Dec 14, 2025

Analyst Upgrade: Why Lantern Pharma Inc stock is rated strong buyTrade Entry Summary & Daily Chart Pattern Signals - moha.gov.vn

Dec 14, 2025

Dec 05, 2025

Lantern Pharma announces LP-184 clinical trial met all primary endpoints - MSN

Dec 05, 2025

Dec 05, 2025

Lake Street Remains a Buy on Lantern Pharma (LTRN) - The Globe and Mail

Dec 05, 2025

Dec 04, 2025

Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors - Digital Journal

Dec 04, 2025